SCHEMBL1997195

SCHEMBL1997195

COc1ccc(C2C(c3ccc(NC(=O)OCc4ccccc4)cc3)C(=O)N2c2cc(OC)c(OC)c(OC)c2)cc1[N+](=O)[O-]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 3/20 0.45
ESR1 P03372 2/20 0.44
CTSV O60911 1/20 0.44
CTSL P07711 1/20 0.44
TSHR P16473 2/20 0.42
ESR2 Q92731 1/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA4 P22748 2/20 0.42
CA7 P43166 2/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
CYP3A4 P08684 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1995917 0.88 HDAC1 (0.53) KMT2AESR1TSHRESR2CA1
SCHEMBL1997163 0.84 CA1 (0.57) ALDH1A1ESR1ESR2CA1CA2
SCHEMBL1995799 0.78 ESR1 (0.52) ALDH1A1ESR1ESR2CA1CA2
SCHEMBL14676233 0.74 TUBB4A (0.55) ALDH1A1ESR1ESR2LMNAHTT
SCHEMBL1993684 0.73 TUBB4A (0.62) MAPTESR1ESR2CA1CA2
SCHEMBL30910093 0.71 ESR1 (0.63) MEN1KMT2AMAPTESR1ESR2
SCHEMBL1997226 0.71 ESR1 (0.63) MEN1KMT2AMAPTESR1ESR2
SCHEMBL14233667 0.70 ESR1 (0.58) ESR1TSHRESR2CA1CA2
SCHEMBL31237891 0.69 CA1 (0.58) ESR1ESR2CA1CA2CA4
SCHEMBL1992128 0.68 CA1 (0.61) ESR1TSHRESR2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120309734-A1 COMBRETASTATIN DERIVATIVES AND USES THEREFOR THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) 2012-12-06 US disclosed
EP-2513051-A1 COMBRETASTATIN DERIVATIVES AND USES THEREFOR The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin (IE) 2012-10-24 EP disclosed
EP-2338877-A1 Combretastatin Derivatives and Uses Therefor The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin (IE) 2011-06-29 EP disclosed
WO-2011073211-A1 COMBRETASTATIN DERIVATIVES AND USES THEREFOR THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309734-A1 COMBRETASTATIN DERIVATIVES AND USES THEREFOR CASP4, CA4, ACSL4 MEN1 1068/4885KMT2A 2424/4885MAPT 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.